# US 2019/0292274 A1 · Binding molecules specific for cd73 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292274 A1
- Document ID: US20190292274A1
- Status: Published application
- Kind: A1
- Application number: 16/375,051
- Filed: 2019-04-04
- Published: 2019-09-26
- Earliest claimed: 2014-11-10
- Assignees: MedImmune, LLC
- Applicants: MedImmune Limited
- Inventors: Carl HAY; Kris SACHSENMEIER; Erin SULT; Qihui HUANG; Peter PAVLIK; Melissa DAMSCHRODER; Li CHENG; Gundo DIEDRICH; Jonathan RIOS-DORIA; Scott HAMMOND; Ralph MINTER; Steve RUST; Sandrine GUILLARD; Robert HOLLINGSWORTH; Lutz JERMUTUS; Nicholas DURHAM; Ching Ching LEOW; Mary ANTONYSAMY; James GEOGHEGAN; Xiaojun LU; Kim ROSENTHAL
- Web page: https://patentgrep.com/patent/US20190292274A1

## CPC

- C07K 16/40: against enzymes
- A61K 47/6825: {Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

## Claims

### Claim 1

A nucleic acid molecule encoding an isolated antibody or antigen-binding fragment thereof that specifically binds to CD73, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain VH domain and a light chain VL domain, the heavy and light chain VH and VL domains comprising:
(a) a VH CDR1 having the amino acid sequence of SEQ ID NO: 36;
(b) a VH CDR2 having the amino acid sequence of SEQ ID NO: 39;
(c) a VH CDR3 having the amino acid sequence of SEQ ID NO: 45;
(d) a VL CDR1 having the amino acid sequence of SEQ ID NO: 46;
(e) a VL CDR2 having the amino acid sequence of SEQ ID NO: 51; and
(f) a VL CDR3 having the amino acid sequence of SEQ ID NO: 56.

### Claim 2 (depends on 1)

An isolated vector comprising the nucleic acid molecule according to claim 1.

### Claim 3 (depends on 2)

An isolated host cell comprising the vector of claim 2.

### Claim 4 (depends on 1, 3)

A method of making the antibody or antigen-binding fragment thereof according to claim 1, comprising (a) culturing the cell of claim 3; and (b) isolating the antibody or antigen-binding fragment thereof.

### Claim 5

A nucleic acid molecule encoding an isolated antibody or antigen-binding fragment thereof that specifically binds to CD73, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain VH domain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain VL domain comprising the amino acid sequence of SEQ ID NO: 68

### Claim 6 (depends on 5)

An isolated vector comprising the nucleic acid molecule according to claim 5.

### Claim 7 (depends on 6)

An isolated host cell comprising the nucleic acid molecule according to claim 6.

### Claim 8 (depends on 5, 7)

A method of making the antibody or antigen-binding fragment thereof according to claim 5, comprising (a) culturing the cell of claim 7; and (b) isolating the antibody or antigen-binding fragment thereof.
